Phase II Study: Docetaxel Plus Oxaliplatin as Second-Line Therapy in Patients With Advanced Metastatic Pancreatic Cancer.

Trial Profile

Phase II Study: Docetaxel Plus Oxaliplatin as Second-Line Therapy in Patients With Advanced Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms DocOx
  • Most Recent Events

    • 02 Jun 2015 Final results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top